» Articles » PMID: 9293786

Specificity of Radioiodinated MIBG for Neural Crest Tumors in Childhood

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 1997 Sep 18
PMID 9293786
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: The high sensitivity of metaiodobenzylguanidine (MIBG) scintigraphy for sympathomedullary tumors such as neuroblastoma and pheochromocytoma is well documented. The specificity of MIBG scintigraphy for these tumors is also high but has been incompletely characterized for other neural crest tumors and non-neural crest tumors of childhood.

Methods: The medical records and MIBG scans of all children who had undergone MIBG scintigraphy for known or suspected neuroblastoma or pheochromocytoma were retrospectively reviewed at five major referral centers. Those patients found to have pathologies other than neuroblastoma or pheochromocytoma form the basis of this study.

Results: One hundred children with a total of 110 lesions met the inclusion criteria. All had negative MIBG scans except 1 of 2 children with infantile myofibromatosis, 1 of 2 with neuroendocrine carcinomas, 1 of 2 with pancreaticoblastomas and 1 of 10 with primitive neuroectodermal tumors.

Conclusion: MIBG scintigraphy is highly specific for neuroblastoma and pheochromocytoma. Only 4% (4/100) of nonsympathomedullary tumors (non-pheochromocytoma and non-neuroblastoma) in childhood showed MIBG uptake, of which only 2% (2/100) were of non-neural crest origin.

Citing Articles

Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine.

Jimenez C, Erwin W, Chasen B Cancers (Basel). 2019; 11(7).

PMID: 31330766 PMC: 6678905. DOI: 10.3390/cancers11071018.


Current status of functional imaging in neuroblastoma, pheochromocytoma, and paraganglioma disease.

Kroiss A Wien Med Wochenschr. 2018; 169(1-2):25-32.

PMID: 30182289 DOI: 10.1007/s10354-018-0658-7.


MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies.

Agrawal A, Rangarajan V, Shah S, Puranik A, Purandare N Br J Radiol. 2018; 91(1091):20180103.

PMID: 30048149 PMC: 6475939. DOI: 10.1259/bjr.20180103.


Guidelines on nuclear medicine imaging in neuroblastoma.

Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman M, Lopci E Eur J Nucl Med Mol Imaging. 2018; 45(11):2009-2024.

PMID: 29938300 DOI: 10.1007/s00259-018-4070-8.


Theranostics in nuclear medicine practice.

Yordanova A, Eppard E, Kurpig S, Bundschuh R, Schonberger S, Gonzalez-Carmona M Onco Targets Ther. 2017; 10:4821-4828.

PMID: 29042793 PMC: 5633297. DOI: 10.2147/OTT.S140671.